MicroRNA‐223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes
Yong He, Seonghwan Hwang, Yan Cai, Seung‐Jin Kim, Mingjiang Xu, Dingcheng Yang, Adrien Guillot, Dechun Feng, Wonhyo Seo, Xin Hou, Bin Gao – 9 April 2019 – Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to more severe forms of liver injury including nonalcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). In humans, only 20%‐40% of patients with fatty liver progress to NASH, and mice fed a high‐fat diet (HFD) develop fatty liver but are resistant to NASH development.